BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thompson DB, Siref LE, Feloney MP, Hauke RJ, Agrawal DK. Immunological basis in the pathogenesis and treatment of bladder cancer. Expert Rev Clin Immunol 2015;11:265-79. [PMID: 25391391 DOI: 10.1586/1744666X.2015.983082] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Nikic P, Dragicevic D, Jerotic D, Savic S, Djukic T, Stankovic B, Kovacevic L, Simic T, Matic M. Polymorphisms of Antioxidant Enzymes SOD2 (rs4880) and GPX1 (rs1050450) Are Associated with Bladder Cancer Risk or Its Aggressiveness. Medicina (Kaunas) 2023;59. [PMID: 36676755 DOI: 10.3390/medicina59010131] [Reference Citation Analysis]
2 Sharifi L, Rezaei N. Immune Checkpoint Inhibitors in Urological Cancers. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_177-1] [Reference Citation Analysis]
3 Afonso R, Fontes J, Pinto P, Romano M, Esteves A. Systemic Bacillus Calmette-Guérin (BCG) Infection With Renal Involvement: A Rare Complication of BCG Immunotherapy. Cureus 2022. [DOI: 10.7759/cureus.33134] [Reference Citation Analysis]
4 Warli SM, Prapiska FF, Siregar DIS, Wijaya WS. Association Between Interleukin-6 Levels and Lymph Node Metastasis in Bladder Cancer Patients. World J Oncol 2022;13:365-9. [PMID: 36660206 DOI: 10.14740/wjon1536] [Reference Citation Analysis]
5 Oufqir Y, Fortin L, Girouard J, Cloutier F, Cloutier M, Leclerc M, Belgorosky D, Eiján AM, Bérubé G, Reyes-moreno C. Synthesis of new para-aminobenzoic acid derivatives, in vitro biological evaluation and preclinical validation of DAB-2-28 as a therapeutic option for the treatment of bladder cancer. European Journal of Medicinal Chemistry Reports 2022;6:100069. [DOI: 10.1016/j.ejmcr.2022.100069] [Reference Citation Analysis]
6 Bitaraf M, Muhammadnejad S, Azimzadeh A, Tanourlouee SB, Amini E, Zolbin MM, Kajbafzadeh AM. Evaluation of direct intramural injection to the bladder wall as a method for developing orthotopic tumor models. Animal Model Exp Med 2022;5:575-81. [PMID: 36451547 DOI: 10.1002/ame2.12293] [Reference Citation Analysis]
7 Yang R, Zhang W, Shang X, Chen H, Mu X, Zhang Y, Zheng Q, Wang X, Liu Y. Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer. Front Pharmacol 2022;13:1013672. [DOI: 10.3389/fphar.2022.1013672] [Reference Citation Analysis]
8 Cloutier F, Oufqir Y, Fortin L, Leclerc M, Girouard J, Tajmir-riahi H, Reyes-moreno C, Bérubé G. Design of novel 4-maleimidylphenyl-hydrazide molecules displaying anti-inflammatory properties: Refining the chemical structure. European Journal of Medicinal Chemistry Reports 2022;5:100064. [DOI: 10.1016/j.ejmcr.2022.100064] [Reference Citation Analysis]
9 You J, Li H, Wei Y, Fan P, Zhao Y, Yi C, Guo Q, Yang X. Novel Pyroptosis-Related Gene Signatures Identified as the Prognostic Biomarkers for Bladder Carcinoma. Front Oncol 2022;12:881860. [DOI: 10.3389/fonc.2022.881860] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lima Cavalcanti ID. Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer. Chemotherapy Protocols and Infusion Sequence 2022. [DOI: 10.1007/978-3-031-10839-6_6] [Reference Citation Analysis]
11 Yan X, Du GW, Chen Z, Liu TZ, Li S. CD86 Molecule Might Be a Novel Immune-Related Prognostic Biomarker for Patients With Bladder Cancer by Bioinformatics and Experimental Assays. Front Oncol 2021;11:679851. [PMID: 34422632 DOI: 10.3389/fonc.2021.679851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Wigner P, Szymańska B, Bijak M, Sawicka E, Kowal P, Marchewka Z, Saluk-Bijak J. Oxidative stress parameters as biomarkers of bladder cancer development and progression. Sci Rep 2021;11:15134. [PMID: 34302052 DOI: 10.1038/s41598-021-94729-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
13 Zheng Z, Zheng X, Zhu Y, Yao Z, Zhao W, Zhu Y, Sun F, Mu X, Wang Y, He W, Liu Z, Wu K, Zheng J. IL-6 Promotes the Proliferation and Immunosuppressive Function of Myeloid-Derived Suppressor Cells via the MAPK Signaling Pathway in Bladder Cancer. Biomed Res Int 2021;2021:5535578. [PMID: 33981768 DOI: 10.1155/2021/5535578] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 El-Gedamy M, El-Khayat Z, Abol-Enein H, El-Said A, El-Nahrery E. Rs-10889677 variant in interleukin-23 receptor may contribute to creating an inflammatory milieu more susceptible to bladder tumourigenesis: report and meta-analysis. Immunogenetics 2021;73:207-26. [PMID: 33665735 DOI: 10.1007/s00251-021-01205-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
15 Xing Q, Liu S, Jiang S, Li T, Wang Z, Wang Y. Prognostic model of 10 immune-related genes and identification of small molecule drugs in bladder urothelial carcinoma (BLCA). Transl Androl Urol 2020;9:2054-70. [PMID: 33209669 DOI: 10.21037/tau-20-696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Busetto GM, Porreca A, Del Giudice F, Maggi M, D'Agostino D, Romagnoli D, Musi G, Lucarelli G, Palmer K, Colonna di Paliano A, Muto M, Hurle R, Terracciano D, de Cobelli O, Sciarra A, De Berardinis E, Ferro M. SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features? Urol Int 2020;104:510-22. [PMID: 32516772 DOI: 10.1159/000509065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
17 Qiu H, Hu X, He C, Yu B, Li Y, Li J. Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes. Front Genet 2020;11:12. [PMID: 32117435 DOI: 10.3389/fgene.2020.00012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 16.7] [Reference Citation Analysis]
18 Jaguva Vasudevan AA, Kreimer U, Schulz WA, Krikoni A, Schumann GG, Häussinger D, Münk C, Goering W. APOBEC3B Activity Is Prevalent in Urothelial Carcinoma Cells and Only Slightly Affected by LINE-1 Expression. Front Microbiol 2018;9:2088. [PMID: 30233553 DOI: 10.3389/fmicb.2018.02088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
19 Ilnitskaya AS, Danilova AB, Baldueva IA. IMMUNOTHERAPY BASED ON DENDRITIC CELLS IN BLADDER CANCER TREATMENT. Usp mol onkol 2018;5:16-23. [DOI: 10.17650/2313-805x-2018-5-2-16-23] [Reference Citation Analysis]
20 Hartana CA, Ahlén Bergman E, Zirakzadeh AA, Krantz D, Winerdal ME, Winerdal M, Johansson M, Alamdari F, Jakubczyk T, Glise H, Riklund K, Sherif A, Winqvist O. Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFβ2 mediated pathway. PLoS One 2018;13:e0200079. [PMID: 29966014 DOI: 10.1371/journal.pone.0200079] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
21 Xiu W, Ma J, Lei T, Zhang M, Zhou S. Immunosuppressive effect of bladder cancer on function of dendritic cells involving of Jak2/STAT3 pathway. Oncotarget 2016;7:63204-14. [PMID: 27556503 DOI: 10.18632/oncotarget.11434] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
22 de Wit M. Urotheltumoren: Immuntherapien auf dem Prüfstand. Deutsches Ärzteblatt Online 2018. [DOI: 10.3238/personko.2018.02.16.02] [Reference Citation Analysis]
23 Rachakonda T, Kendall B, Spivak AM, Boltax J. Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer. Open Forum Infectious Diseases 2017;4. [DOI: 10.1093/ofid/ofx126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Bianconi M, Faloppi L, Lopez-beltran A, Cheng L, Cimadamore A, Gasparrini S, Massari F, Scarpelli M, Montironi R. Immunotherapy in genitourinary cancers: where are we going? Expert Review of Precision Medicine and Drug Development 2017;2:73-8. [DOI: 10.1080/23808993.2017.1321466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Mingozzi F, Spreafico R, Gorletta T, Cigni C, Di Gioia M, Caccia M, Sironi L, Collini M, Soncini M, Rusconi M, von Andrian UH, Chirico G, Zanoni I, Granucci F. Prolonged contact with dendritic cells turns lymph node-resident NK cells into anti-tumor effectors. EMBO Mol Med 2016;8:1039-51. [PMID: 27406819 DOI: 10.15252/emmm.201506164] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
26 Purves JT, Hughes FM Jr. Inflammasomes in the urinary tract: a disease-based review. Am J Physiol Renal Physiol 2016;311:F653-62. [PMID: 27170685 DOI: 10.1152/ajprenal.00607.2015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
27 Liu Q, Tian Y, Zhao X, Jing H, Xie Q, Li P, Li D, Yan D, Zhu X. NMAAP1 Expressed in BCG-Activated Macrophage Promotes M1 Macrophage Polarization. Mol Cells 2015;38:886-94. [PMID: 26429502 DOI: 10.14348/molcells.2015.0125] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]